|
**Overview**: **HCC Profile****Introduction**: The HCC Profile is a diagnostic tool designed to screen for hepatocellular carcinoma using serum samples. Associated with conditions like liver cancer and cirrhosis, these disorders present with weight loss, jaundice, and severe complications if untreated, particularly in individuals with suspected liver malignancy. Per the 2023 Biochemistry and Serology guidelines, the test employs biochemistry and serology with immunoassay and spectrophotometry technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for cancer screening in clinical settings. This diagnostic falls under cancer screening and targets individuals with risk factors for hepatocellular carcinoma, addressing the challenge of accurate tumor marker assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: HCC Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry and serology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by oncology labs, this test advanced HCC screening.**Purpose**: The test screens for 36 parameters including AFP to guide HCC assessment, assess tumor markers and liver function, and inform treatment and prevention strategies.**Test Parameters**: 1. AFP, 2. Des-Gamma-Carboxy Prothrombin (DCP), 3. Total Bilirubin, 4. Direct Bilirubin, 5. AST, 6. ALT, 7. ALP, 8. GGT, 9. Total Protein, 10. Albumin, 11. Globulin, 12. Prothrombin Time, 13. INR, 14. HBsAg, 15. Anti-HBc Total, 16. Anti-HCV, 17. CEA, 18. CA 19-9, 19. Ferritin, 20. Alpha-1-Antitrypsin, 21. Ceruloplasmin, 22. Transferrin, 23. Haptoglobin, 24. Creatinine, 25. Urea, 26. Sodium, 27. Potassium, 28. Calcium, 29. Phosphorus, 30. Platelet Count, 31. Hemoglobin, 32. WBC Count, 33. ESR, 34. Apolipoprotein A1, 35. Apolipoprotein B, 36. FibroTest.**Pretest Condition**: No fasting required; patients should report weight loss, jaundice, or recent liver symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on weight loss, jaundice, prior liver reactions, or family history of liver cancer, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated HCC including metastasis, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and spectrophotometry and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent liver therapy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible HCC, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in oncology or hepatology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Imaging or biopsy for confirmation.**Test Limitations**: The test may produce false negatives in early cancer stages or false positives in liver inflammation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry and Serology Guidelines 2023, Journal of Oncology 2024, Chemistry 2025. |
